June 2, 2021
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7561
We have read Item 4.01 of Spectrum Pharmaceuticals, Inc.'s Form 8-K dated June 2, 2021, and have the following comments:
1. We agree with the statements made in the second, third, and fourth paragraphs of 4.01(a).
2. We have no basis on which to agree or disagree with the statements made in the first paragraph of 4.01(a), and 4.01(b).
/s/ Deloitte & Touche LLP
Spectrum Pharmaceuticals Inc. published this content on 02 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 June 2021 20:28:01 UTC.